Being Patient’s Post

Read our new article in Drug Discovery World! It's estimated that up to half of all #type2diabetes patients will develop some form of diabetic retinopathy within 20 years. Despite this, current treatment strategies are both invasive and limited, imposing a considerable burden on patients and greatly affecting their quality of life. Dr Catherine Beech MB,ChB,OBE and Dr Pete Adamson (Breye Therapeutics ApS) discuss the challenges presented by current treatments for diabetic #eyedisease, and outline innovative research and studies that are paving the way for a new-generation of therapies. Find the latest print issue: https://rb.gy/mv3c5o

Pluvicto attacks the tumor while avoiding unnecessary radiation exposure that can limit the efficacy and tolerability of traditional radiation therapy options. Read more 👉 https://lttr.ai/AWgbQ #Pharmacist #Healthcare #Quality #Chemotherapy #ProstateSpecificMembraneAntigen #CausingCellDeath #ClinicalTrialsRelated #StudySPatientPopulation #VarySubstantiallyDepending #ProvideDefinitiveConclusions

Palatin Initiates Phase 2 Clinical Study of Bremelanotide.The clinical study will evaluate the safety and efficacy of bremelanotide, a melanocortin 4 receptor (MC4R) agonist, co-administered with tirzepatide (GLP-1/GIP) in obese patients #obesity #clinicaltrials BioSpace https://lnkd.in/gVE4UWBK

Cardio World Congress 2024 in Prague, Czech Republic, June 25 – 26, 2024   Learn about our recent research results and progress in development of HFpEF therapy: Wednesday, June 26, at 10:50 a.m., in the session on “Cardiovascular Pharmacology & Diabetes, Hypertension and Obesity” Thomas Bernd Dschietzig, Relaxera, gives a presentation about “The development of human relaxin-2 for Heart Failure with preserved ejection fraction, HFpEF”.   Relaxera is addressing the needs of HFpEF patients to provide a drug against HFpEF which is not only alleviating symptoms. Our target is to transform the therapy landscape by addressing the multiple causes and drivers of this complex disease.   https://lnkd.in/e9DFqQpP

This afternoon, Rajesh Khanna, Ph.D., Richard and Thelma O.C. Barney Term Professor and Director of Pain and Addiction Therapeutics (PATH) Collaboratory Pharmacology & Therapeutics at University of Florida College of Medicine, presented a insightful talk titled, A peptidomimetic modulator of the CaV2.2 N-type calcium channel for chronic pain.' You can view the abstract here >

Researchers Serpil Aygörmez and Şaban Maraşli from Kafkas University explored the effects of curcumin (CUR) and piperine (PP) on cyclophosphamide (CP)-induced brain damage in rats. Their study aimed to assess whether a combination of CUR and PP could mitigate the neurotoxic effects commonly associated with CP, an antineoplastic drug. The findings revealed that while CP caused significant brain damage, the CUR-PP combination reduced inflammation and oxidative stress markers, suggesting its potential as a neuroprotective agent. This study highlights the therapeutic promise of CUR and PP in managing chemotherapy-induced neurotoxicity. Link : https://lnkd.in/gVtHg25w #Neuroprotection #Curcumin #Piperine #Chemotherapy #BrainHealth #MedicalResearch

Researchers Serpil Aygörmez and Şaban Maraşli from Kafkas University explored the effects of curcumin (CUR) and piperine (PP) on cyclophosphamide (CP)-induced brain damage in rats. Their study aimed to assess whether a combination of CUR and PP could mitigate the neurotoxic effects commonly associated with CP, an antineoplastic drug. The findings revealed that while CP caused significant brain damage, the CUR-PP combination reduced inflammation and oxidative stress markers, suggesting its potential as a neuroprotective agent. This study highlights the therapeutic promise of CUR and PP in managing chemotherapy-induced neurotoxicity. Link : https://lnkd.in/gVtHg25w #Neuroprotection #Curcumin #Piperine #Chemotherapy #BrainHealth #MedicalResearch

Should we combine propranolol & primidone in the treatment of essential tremor (ET) ? Mechanisms of tremor-modulating effects of primidone and propranolol in essential tremor Primidone operates in vivo to mitigate ET by inhibiting voltage-gated sodium channels and engaging with GABA-A intracortical circuits, aligning with prior preclinical hypotheses. The results on CSP, LICI and SICI indicate even stronger involvement of intracortical GABA-B intracortical circuits with primidone, marking a novel discovery in our study. Primidone was more effective in those patients with more preserved EBCC, suggesting its efficacy could also be attributed to binding to GABAergic receptors in the cerebellum. The influence of propranolol on the rest IO curve and SAI implies that, beyond its well-known peripheral effects, central action also plays a role in its effectiveness in ET. IAPRD Secretariat Full article: https://lnkd.in/gf7_dcTZ

🔬 Breakthrough in Temporomandibular Joint Osteoarthritis Treatment: Near-Infrared Light Activation🔬 This clinical research study presents a breakthrough in the treatment of Temporomandibular Joint Osteoarthritis (TMJOA). The study introduces a novel drug delivery system that combines photothermal therapy and chemotherapy, addressing the limitations of traditional treatments such as side effects and suboptimal responsiveness. The researchers developed a Near-Infrared (NIR) light-sensitive drug delivery system using Mesoporous Polydopamine Nanospheres (MPDA). Upon exposure to an 808 nm NIR laser, this system raises the temperature to the melting point of the drug administrator, 1-tetradecanol (TD), thereby triggering the release of the anti-inflammatory drug, Diclofenac Sodium (DS). The system demonstrated a strong photothermal effect and effectively controlled the release of DS. Both in vitro and in vivo trials showed promising results. After 14 days of injecting the system into the TMJ of rats with TMJOA, there was a significant reduction in the deterioration of TMJ cartilage. 💡 This research offers a ray of hope for TMJOA patients and contributes significantly to improving treatment strategies. Source: https://bit.ly/3wQoncN #ClinicalResearch #TMJOA #PhotothermalTherapy #Chemotherapy #DrugDelivery #Innovation #OsteoarthritisResearch #NIRlaser #ControlledRelease #MesoporousPolydopamineNanospheres #Breakthrough #MedicalResearch #kaiyanmedical